Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: New Data: “Admission-First” AI ...

Their solution, VetEvince, went beyond simple automation or AI chat assistants. It promised to deliver insights anchored in ...

Adopted nationwide, Amissa is the first clinical intelligence platform for menopause—turning fragmented care into ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

Strong evidence supports the use of AI-powered portable MRI for stroke detection in multiple clinical settings, including the emergency department.

Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...

BioNTech will present significant clinical trial data at the prestigious ASCO Annual Meeting, highlighting the advancement of its diversified oncology portfolio. The preliminary results for BNT327 and ...

Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

Jasper Therapeutics, Inc. announced that it is presenting updated clinical data from its Phase 1b/2a BEACON study on briquilimab, an antibody therapy targeting c-Kit to treat mast cell-driven diseases ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three ...

When trial participants aren't representative, the evidence for universally adopted cancer treatment guidelines is incomplete ...

The placebo-controlled, double-blind, randomised Phase I trial involved 100 healthy participants.